Strata Oncology Announces Launch and Medicare Coverage for Strata Select, a First-of-its-kind Immunotherapy Test

Strata Oncology, Inc. (“Strata”), a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the launch of Strata Select^TM, a first-of-its-kind molecular profiling test for patients with advanced cancer. The new diagnostic test features the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit.